Centre for Primary Care and Public Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, USA.
J Bone Miner Res. 2013 Jun;28(6):1301-7. doi: 10.1002/jbmr.1855.
Animal models suggest a key role for dihydroxylated vitamin D metabolites in fracture healing, as evidenced by increases in serum concentration of 24R,25-dihydroxyvitamin D (24R,25[OH]₂D) after long bone fracture. Human studies investigating the kinetics of serum concentrations of 24R,25[OH]₂D, 1,25-dihydroxyvitamin D (1,25[OH]₂D) and their parent metabolite 25-hydroxyvitamin D (25[OH]D) are lacking. We, therefore, conducted a longitudinal study to determine whether total, free, or bioavailable concentrations of these vitamin D metabolites fluctuate in humans after long bone fracture. Twenty-eight patients with cross-shaft (diaphyseal) long bone fracture presenting to an emergency department in London, UK, were studied. Serum concentrations of 25(OH)D, 24R,25(OH)₂D, 1,25(OH)₂D, vitamin D binding protein, albumin, and calcium were determined within 48 hours of fracture and again at 1 and 6 weeks postfracture. Concentrations of free and bioavailable vitamin D metabolites were calculated using standard equations. No changes in mean serum concentrations of 25(OH)D or 24R,25(OH)₂D were seen at either follow-up time point versus baseline. In contrast, mean serum 1,25(OH)2 D concentration declined by 21% over the course of the study, from 68.5 pmol/L at baseline to 54.1 pmol/L at 6 weeks (p < 0.05). This decline was associated with an increase in mean serum corrected calcium concentration, from 2.32 mmol/L at baseline to 2.40 mmol/L at 1 week (p < 0.001) that was maintained at 6 weeks. No changes in free or bioavailable concentrations of any vitamin D metabolite investigated were seen over the course of the study. We conclude that serum 1,25(OH)₂D concentration declines after long bone fracture in humans but that the serum 24R,25(OH)₂D concentration does not fluctuate. The latter finding contrasts with those of animal models reporting increases in serum 24R,25(OH)₂D concentration after long bone fracture.
动物模型表明二羟维生素 D 代谢物在骨折愈合中起着关键作用,这可以从长骨骨折后血清 24R,25-二羟维生素 D(24R,25[OH]₂D)浓度的增加得到证明。目前缺乏研究血清 24R,25[OH]₂D、1,25-二羟维生素 D(1,25[OH]₂D)及其母体代谢物 25-羟维生素 D(25[OH]D)浓度动力学的人体研究。因此,我们进行了一项纵向研究,以确定长骨骨折后这些维生素 D 代谢物的总浓度、游离浓度或生物利用度是否在人体中波动。28 名患有骨干(骨干)长骨骨折的患者在英国伦敦的一家急诊科就诊。在骨折后 48 小时内和骨折后 1 周和 6 周再次测定血清 25(OH)D、24R,25(OH)₂D、1,25(OH)₂D、维生素 D 结合蛋白、白蛋白和钙的浓度。使用标准方程计算游离和生物利用度维生素 D 代谢物的浓度。与基线相比,在任何随访时间点,血清 25(OH)D 或 24R,25(OH)₂D 的平均血清浓度均无变化。相比之下,1,25(OH)₂D 血清浓度在研究过程中下降了 21%,从基线时的 68.5 pmol/L 降至 6 周时的 54.1 pmol/L(p<0.05)。这种下降与平均血清校正钙浓度的增加有关,从基线时的 2.32 mmol/L 增加到 1 周时的 2.40 mmol/L(p<0.001),并在 6 周时保持不变。在研究过程中,未观察到任何研究的维生素 D 代谢物的游离或生物利用度浓度发生变化。我们的结论是,长骨骨折后人类血清 1,25(OH)₂D 浓度下降,但血清 24R,25(OH)₂D 浓度并未波动。这一发现与报告长骨骨折后血清 24R,25(OH)₂D 浓度增加的动物模型的结果相反。